Published in Managed Care Weekly Digest, April 12th, 2004
The rate moved from approximately $1,304 to $1,404, as part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - this rate was determined using the Average Selling Price for Visudyne in Q4 2003 +6%.
In December 2003 and January 2004, QLT and Novartis provided information to CMS requesting an exception to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and an appropriate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest